259 related articles for article (PubMed ID: 27797889)
1. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.
de Boer IH; Gao X; Cleary PA; Bebu I; Lachin JM; Molitch ME; Orchard T; Paterson AD; Perkins BA; Steffes MW; Zinman B;
Clin J Am Soc Nephrol; 2016 Nov; 11(11):1969-1977. PubMed ID: 27797889
[TBL] [Abstract][Full Text] [Related]
2. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study.
Molitch ME; Steffes M; Sun W; Rutledge B; Cleary P; de Boer IH; Zinman B; Lachin J;
Diabetes Care; 2010 Jul; 33(7):1536-43. PubMed ID: 20413518
[TBL] [Abstract][Full Text] [Related]
3. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.
de Boer IH; Rue TC; Cleary PA; Lachin JM; Molitch ME; Steffes MW; Sun W; Zinman B; Brunzell JD; ; White NH; Danis RP; Davis MD; Hainsworth D; Hubbard LD; Nathan DM
Arch Intern Med; 2011 Mar; 171(5):412-20. PubMed ID: 21403038
[TBL] [Abstract][Full Text] [Related]
4. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
5. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study.
DCCT/EDIC research group
Lancet Diabetes Endocrinol; 2014 Oct; 2(10):793-800. PubMed ID: 25043685
[TBL] [Abstract][Full Text] [Related]
6. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.
de Boer IH;
Diabetes Care; 2014; 37(1):24-30. PubMed ID: 24356594
[TBL] [Abstract][Full Text] [Related]
7. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.
Ferreira JP; Zannad F; Butler J; Filippatos G; Pocock SJ; Brueckmann M; Steubl D; Schueler E; Anker SD; Packer M
JAMA Cardiol; 2022 Nov; 7(11):1148-1159. PubMed ID: 36129693
[TBL] [Abstract][Full Text] [Related]
8. Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT).
Kern EF; Erhard P; Sun W; Genuth S; Weiss MF
Am J Kidney Dis; 2010 May; 55(5):824-34. PubMed ID: 20138413
[TBL] [Abstract][Full Text] [Related]
9. Renal outcomes in patients with type 1 diabetes and macroalbuminuria.
de Boer IH; Afkarian M; Rue TC; Cleary PA; Lachin JM; Molitch ME; Steffes MW; Sun W; Zinman B;
J Am Soc Nephrol; 2014 Oct; 25(10):2342-50. PubMed ID: 24925722
[TBL] [Abstract][Full Text] [Related]
10. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
11. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.
Koye DN; Magliano DJ; Reid CM; Jepson C; Feldman HI; Herman WH; Shaw JE
Am J Kidney Dis; 2018 Nov; 72(5):653-661. PubMed ID: 29784612
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Progression of Chronic Kidney Disease in Black and White Individuals with Type 2 Diabetes.
Gerber C; Cai X; Lee J; Craven T; Scialla J; Souma N; Srivastava A; Mehta R; Paluch A; Hodakowski A; Frazier R; Carnethon MR; Wolf MS; Isakova T
Clin J Am Soc Nephrol; 2018 Jun; 13(6):884-892. PubMed ID: 29798889
[TBL] [Abstract][Full Text] [Related]
13. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
Muskiet MHA; Tonneijck L; Huang Y; Liu M; Saremi A; Heerspink HJL; van Raalte DH
Lancet Diabetes Endocrinol; 2018 Nov; 6(11):859-869. PubMed ID: 30292589
[TBL] [Abstract][Full Text] [Related]
14. Regression of albuminuria and its association with incident cardiovascular outcomes and mortality in type 1 diabetes: the FinnDiane Study.
Jansson FJ; Forsblom C; Harjutsalo V; Thorn LM; Wadén J; Elonen N; Ahola AJ; Saraheimo M; Groop PH;
Diabetologia; 2018 May; 61(5):1203-1211. PubMed ID: 29423580
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Albuminuria on Cardiovascular Outcomes After Elective Percutaneous Coronary Intervention.
Kunimura A; Ishii H; Uetani T; Harada K; Kataoka T; Takeshita M; Harada K; Okumura S; Shinoda N; Kato B; Kato M; Suzuki S; Amano T; Murohara T
Am J Cardiol; 2016 Mar; 117(5):714-9. PubMed ID: 26772442
[TBL] [Abstract][Full Text] [Related]
16. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
17. Systematic review on urine albumin testing for early detection of diabetic complications.
Newman DJ; Mattock MB; Dawnay AB; Kerry S; McGuire A; Yaqoob M; Hitman GA; Hawke C
Health Technol Assess; 2005 Aug; 9(30):iii-vi, xiii-163. PubMed ID: 16095545
[TBL] [Abstract][Full Text] [Related]
18. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
19. The estimated glomerular filtration rate is associated with subclinical atherosclerosis, independently of albuminuria, in patients with type 2 diabetes.
Lu B; Wan J; Yang Y; Li Y; Hu R
Int Angiol; 2013 Oct; 32(5):532-9. PubMed ID: 23903314
[TBL] [Abstract][Full Text] [Related]
20. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
Heerspink HJ; Persson F; Brenner BM; Chaturvedi N; Brunel P; McMurray JJ; Desai AS; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D
Lancet Diabetes Endocrinol; 2016 Apr; 4(4):309-17. PubMed ID: 26774608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
